

Annex N3

**ICCVAM/NICEATM BG1Luc4E2 ER TA – Bibliography for the ER Binding and
Transcriptional Activation Literature Update**

This page intentionally left blank

Akahori Y, Nakai M, Yamasaki K, Takatsuki M, Shimohigashi Y, Ohtaki M. 2008. Relationship between the results of *in vitro* receptor binding assay to human estrogen receptor alpha and *in vivo* uterotrophic assay: comparative study with 65 selected chemicals. *Toxicol In Vitro* 22(1): 225-231.

Albanito L, Lappano R, Madeo A, Chimento A, Prossnitz ER, Cappello AR, et al. 2008. G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells. In: *Environ Health Perspect*, 1648-1655. Epub 2008 Jul 1622.

Amita M, Takahashi T, Tsutsumi S, Ohta T, Takata K, Henmi N, et al. 2010. Molecular mechanism of the inhibition of estradiol-induced endometrial epithelial cell proliferation by clomiphene citrate. *Endocrinology* 151(1): 394-405.

Andersen HR, Bonfeld-Jorgensen EC, Nielsen F, Jarfeldt K, Jayatissa MN, Vinggaard AM. 2006. Estrogenic effects *in vitro* and *in vivo* of the fungicide fenarimol. *Toxicology Letters* 163(2): 142-152.

Attardi BJ, Page ST, Hild SA, Coss CC, Matsumoto AM. 2010. Mechanism of action of bolandiol (19-nortestosterone-3beta,17beta-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activities. *J Steroid Biochem Mol Biol* 118(3): 151-161.

Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. 1998. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. *Mol Pharmacol* 54(1): 105-112.

Baumann RJ, Bush TL, Cross-Doersen DE, Cashman EA, Wright PS, Zwolshen JH, et al. 1998. Clomiphene analogs with activity *in vitro* and *in vivo* against human breast cancer cells. *Biochem Pharmacol* 55(6): 841-851.

Berckmans P, Leppens H, Vangenechten C, Witters H. 2007. Screening of endocrine disrupting chemicals with MELN cells, an ER-transactivation assay combined with cytotoxicity assessment. *Toxicol In Vitro* 21(7): 1262-1267.

Berthier A, Girard C, Grandvuillemin A, Muyard F, Skaltsounis AL, Jouvenot M, et al. 2007. Effect of 7-O-beta-D-glucopyranosylchrysin and its aglycone chrysin isolated from *Podocytisus caramanicus* on estrogen receptor alpha transcriptional activity. In: *Planta Med*, 1447-1451. Epub 2007 Oct 1419.

Berube G, Rabouin D, Perron V, N'Zemba B, Gaudreault RC, Parent S, et al. 2006. Synthesis of unique 17beta-estradiol homo-dimers, estrogen receptors binding affinity evaluation and cytotoxic activity on breast, intestinal and skin cancer cell lines. In: *Steroids*, 911-921. Epub 2006 Aug 2017.

Bhat KPL, Kosmeder JW, 2nd, Pezzuto JM. 2001a. Biological effects of resveratrol. *Antioxid Redox Signal* 3(6): 1041-1064.

Bhat KPL, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM. 2001b. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. *Cancer Research* 61(20): 7456-7463.

Bhat KPL, Pezzuto JM. 2001. Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. *Cancer Research* 61(16): 6137-6144.

Bhavnani BR, Tam SP, Lu X. 2008. Structure activity relationships and differential interactions and functional activity of various equine estrogens mediated via estrogen receptors (ERs) ERalpha and ERbeta. In: *Endocrinology*, 4857-4870. Epub 2008 Jul 4853.

- Bonefeld-Jorgensen EC, Long M, Hofmeister MV, Vinggaard AM. 2007. Endocrine-disrupting potential of bisphenol A, bisphenol A dimethacrylate, 4-n-nonylphenol, and 4-n-octylphenol *in vitro*: new data and a brief review. In: Environ Health Perspect, 69-76.
- Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. 2000. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141(10): 3657-3667.
- Buteau-Lozano H, Velasco G, Cristofari M, Balaguer P, Perrot-Applanat M. 2008. Xenoestrogens modulate vascular endothelial growth factor secretion in breast cancer cells through an estrogen receptor-dependent mechanism. J Endocrinol 196(2): 399-412.
- Buterin T, Koch C, Naegeli H. 2006. Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis 27(8): 1567-1578.
- Byford J, Shaw L, Drew M, Pope G, Sauer M, Darbre P. 2002. Oestrogenic activity of parabens in MCF7 human breast cancer cells. Journal of Steroid Biochemistry & Molecular Biology 80: 49-60.
- Choi SY, Ha TY, Ahn JY, Kim SR, Kang KS, Hwang IK, et al. 2008. Estrogenic activities of isoflavones and flavones and their structure-activity relationships. Planta Med 74(1): 25-32.
- Chrzan BG, Bradford PG. 2007. Phytoestrogens activate estrogen receptor beta1 and estrogenic responses in human breast and bone cancer cell lines. Mol Nutr Food Res 51(2): 171-177.
- Dardes RC, Schafer JM, Pearce ST, Osipo C, Chen B, Jordan VC. 2002. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells. Gynecol Oncol 85(3): 498-506.
- Dayan G, Lupien M, Auger A, Anghel SI, Rocha W, Croisetiere S, et al. 2006. Tamoxifen and raloxifene differ in their functional interactions with aspartate 351 of estrogen receptor alpha. Mol Pharmacol 70(2): 579-588.
- Di X, Yu L, Moore AB, Castro L, Zheng X, Hermon T, et al. 2008. A low concentration of genistein induces estrogen receptor-alpha and insulin-like growth factor-I receptor interactions and proliferation in uterine leiomyoma cells. Hum Reprod 23(8): 1873-1883.
- Escande A, Pillon A, Servant N, Cravedi J-P, Larrea F, Muhn P, et al. 2006. Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta. Biochemical Pharmacology 71(10): 1459-1469.
- Evans RM, Rahte S, Kortenkamp A. 2010. Inability to confirm estrogenicity of the heterocyclic amine PhIP in two *in vitro* assays. Toxicol In Vitro 24(6): 1757-63.
- Freyberger A, Schmuck G. 2004. Screening for estrogenicity and anti-estrogenicity: a critical evaluation of an MVLN cell-based transactivation assay. Toxicology Letters 155(1): 1-13.
- Freyberger A, Wilson V, Weimer M, Tan S, Tran HS, Ahr HJ. 2010. Assessment of a robust model protocol with accelerated throughput for a human recombinant full length estrogen receptor-alpha binding assay: Protocol optimization and intralaboratory assay performance as initial steps towards validation. Reprod Toxicol 30(1):50-9.
- Fujimoto N, Jinno N, Kitamura S. 2004. Activation of estrogen response element dependent transcription by thyroid hormone with increase in estrogen receptor levels in a rat pituitary cell line, GH3. J Endocrinol 181(1): 77-83.
- Fujita T, Kobayashi Y, Wada O, Tateishi Y, Kitada L, Yamamoto Y, et al. 2003. Full activation of estrogen receptor alpha activation function-1 induces proliferation of breast cancer cells. J Biol Chem 278(29): 26704-26714.

Gehm B, McAndrews J, Chien P, Jameson J. 1997. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. *Proc Natl Acad Sci USA* 94: 14138-14143.

Ghisari M, Bonefeld-Jorgensen EC. 2009. Effects of plasticizers and their mixtures on estrogen receptor and thyroid hormone functions. *Toxicology Letters* 189(1): 67-77.

Gomez E, Pillon A, Fenet H, Rosain D, Duchesne MJ, Nicolas JC, et al. 2005. Estrogenic activity of cosmetic components in reporter cell lines: parabens, UV screens, and musks. *J Toxicol Environ Health A* 68(4): 239-251.

Gougelet A, Mueller SO, Korach KS, Renoir JM. 2007. Oestrogen receptors pathways to oestrogen responsive elements: the transactivation function-1 acts as the keystone of oestrogen receptor (ER)beta-mediated transcriptional repression of ERalpha. *J Steroid Biochem Mol Biol* 104(3-5): 110-122.

Gungor T, Chen Y, Golla R, Ma Z, Corte JR, Northrop JP, et al. 2006. Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators. *J Med Chem* 49(8): 2440-2455.

Gutendorf B, Westendorf J. 2001. Comparison of an array of *in vitro* assays for the assessment of the estrogenic potential of natural and synthetic estrogens, phytoestrogens and xenoestrogens. *Toxicology* 166(1-2): 79-89.

Harris DM, Besselink E, Henning SM, Go VLW, Heber D. 2005. Phytoestrogens induce differential estrogen receptor alpha- or beta-mediated responses in transfected breast cancer cells. *Experimental Biology and Medicine* 230(8): 558-568.

Hershberger PA, Stabile LP, Kanterewicz B, Rothstein ME, Gubish CT, Land S, et al. 2009. Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. *J Steroid Biochem Mol Biol* 116(1-2): 102-109.

Hillerns P, Zu Y, Fu Y-J, Wink M. 2005. Binding of phytoestrogens to rat uterine estrogen receptors and human sex hormone-binding globulins. *Z Naturforsch C*, 60(7-8):649-56.

Hirsch K, Atzmon A, Danilenko M, Levy J, Sharoni Y. 2007. Lycopene and other carotenoids inhibit estrogenic activity of 17beta-estradiol and genistein in cancer cells. *Breast Cancer Res Treat* 104(2):221-30.

Hwang CS, Kwak HS, Lim HJ, Lee SH, Kang YS, Choe TB, et al. 2006. Isoflavone metabolites and their *in vitro* dual functions: they can act as an estrogenic agonist or antagonist depending on the estrogen concentration. *J Steroid Biochem Mol Biol* 101(4-5): 246-253.

Innocenti G, Vegeto E, Dall'Acqua S, Ciana P, Giorgetti M, Agradi E, et al. 2007. *In vitro* estrogenic activity of *Achillea millefolium* L. *Phytomedicine* 14(2-3):147-52.

Jordan VC, Jeng MH, Catherino WH, Parker CJ. 1993. The estrogenic activity of synthetic progestins used in oral contraceptives. *Cancer* 71(4 Suppl): 1501-1505.

Joung K, Kim Y, Sheen Y. 2003. Assessment of the estrogenicity of isoflavonoids, using MCF-7-ERE-Luc cells. *Arch Pharm Res* 26(9): 756-762.

Jung J, Ishida K, Nishikawa J, Nishihara T. 2007. Inhibition of estrogen action by 2-phenylchromone as AhR agonist in MCF-7 cells. *Life Sciences* 81(19-20): 1446-1451.

Klinge CM, Risinger KE, Watts MB, Beck V, Eder R, Jungbauer A. 2003. Estrogenic activity in white and red wine extracts. *J Agric Food Chem* 51(7): 1850-1857.

- Kojima H, Katsura E, Takeuchi S, Niiyama K, Kobayashi K. 2004. Screening for estrogen and androgen receptor activities in 200 pesticides by *in vitro* reporter gene assays using Chinese hamster ovary cells. *Environmental Health Perspectives* 112(5): 524-531.
- Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. 2005. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. *Endocrinology* 146(9): 3999-4008.
- Kurosawa T, Hiroi H, Tsutsumi O, Ishikawa T, Osuga Y, Fujiwara T, et al. 2002. The activity of bisphenol A depends on both the estrogen receptor subtype and the cell type. *Endocr J* 49(4): 465-471.
- Kuruto-Niwa R, Ito T, Goto H, Nakamura H, Nozawa R, Terao Y. 2007. Estrogenic activity of the chlorinated derivatives of estrogens and flavonoids using a GFP expression system. *Environmental Toxicology and Pharmacology* 23(1): 121.
- Lappano R, Rosano C, Madeo A, Albanito L, Plastina P, Gabriele B, et al. 2009. Structure-activity relationships of resveratrol and derivatives in breast cancer cells. *Mol Nutr Food Res* 53(7): 845-858.
- Larrosa M, Gonzalez-Sarrias A, Garcia-Conesa MT, Tomas-Barberan FA, Espin JC. 2006. Urolithins, ellagic acid-derived metabolites produced by human colonic microflora, exhibit estrogenic and antiestrogenic activities. *J Agric Food Chem* 54(5): 1611-1620.
- Leblanc K, Sexton E, Parent S, Belanger G, Dery MC, Boucher V, et al. 2007. Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens. *Int J Oncol* 30(2): 477-487.
- Lemaire G, Mnif W, Mauvais P, Balaguer P, Rahmani R. 2006. Activation of alpha- and beta-estrogen receptors by persistent pesticides in reporter cell lines. *Life Sciences* 79(12): 1160-1169.
- Leung LK, Po LS, Yuen YM. 2004. Effect of dietary flavonols on oestrogen receptor transcription and cell death induction. *British Journal of Nutrition* 91(6): 831-839.
- Liu S, Abdelrahim M, Khan S, Ariazi E, Jordan VC, Safe S. 2006. Aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha in MCF-7 breast cancer cells. *Biol Chem* 387(9):1209-13.
- Long X, Fan M, Bigsby RM, Nephew KP. 2008. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms. *Mol Cancer Ther* 7(7): 2096-2108.
- Lui K, Tamura T, Mori T, Zhou D, Chen S. 2008. MCF-7aro/ERE, a novel cell line for rapid screening of aromatase inhibitors, ERalpha ligands and ERRalpha ligands. *Biochem Pharmacol* 76(2): 208-215.
- Maggiolini M, Bonofiglio D, Marsico S, Panno ML, Cenni B, Picard D, et al. 2001. Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. *Mol Pharmacol* 60(3): 595-602.
- Maggiolini M, Recchia AG, Carpino A, Vivacqua A, Fasanella G, Rago V, et al. 2004. Oestrogen receptor b is required for androgen-stimulated proliferation of LNCaP prostate cancer cells. *Journal of Molecular Endocrinology* 32(3): 777-791.
- Mak P, Leung YK, Tang WY, Harwood C, Ho SM. 2006. Apigenin suppresses cancer cell growth through ERbeta. *Neoplasia* 8(11): 896-904.

- Maru BS, Tobias JH, Rivers C, Caunt CJ, Norman MR, McArdle CA. 2009. Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity. *Bone* 44(1): 102-112.
- Nakamura T, Katsu Y, Watanabe H, Iguchi T. 2008. Estrogen receptor subtypes selectively mediate female mouse reproductive abnormalities induced by neonatal exposure to estrogenic chemicals. *Toxicology* 253(1-3):117-24.
- Ni YD, Hong WJ, Zhou YC, Grossmann R, Zhao RQ. 2010. Dual effects of daidzein on chicken hepatic vitellogenin II expression and estrogen receptor-mediated transactivation *in vitro*. *Steroids*.
- Nose T, Tokunaga T, Shimohigashi Y. 2009. Exploration of endocrine-disrupting chemicals on estrogen receptor alpha by the agonist/antagonist differential-docking screening (AADS) method: 4-(1-adamantyl)phenol as a potent endocrine disruptor candidate. *Toxicol Lett* 91(1):33-9.
- Oh SM, Kim YP, Chung KH. 2006. Biphasic effects of kaempferol on the estrogenicity in human breast cancer cells. *Arch Pharm Res* 29(5): 354-362.
- Overk CR, Peng KW, Asghodom RT, Kastrati I, Lantvit DD, Qin Z, et al. 2007. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene. *ChemMedChem* 2(10): 1520-1526.
- Park SH, Kim KY, An BS, Choi JH, Jeung EB, Leung PC, et al. 2009. Cell growth of ovarian cancer cells is stimulated by xenoestrogens through an estrogen-dependent pathway, but their stimulation of cell growth appears not to be involved in the activation of the mitogen-activated protein kinases ERK-1 and p38. *J Reprod Dev* 55(1):23-9.
- Pillon A, Servant N, Vignon F, Balaguer P, Nicolas JC. 2005. *In vivo* bioluminescence imaging to evaluate estrogenic activities of endocrine disrupters. *Anal Biochem* 340(2): 295-302.
- Preuss TG, Gurer-Orhan H, Meerman J, Ratte HT. 2010. Some nonylphenol isomers show antiestrogenic potency in the MVLN cell assay. *Toxicol In Vitro* 24(1): 129-134.
- Pugazhendhi D, Watson KA, Mills S, Botting N, Pope GS, Darbre PD. 2008. Effect of sulphonation on the oestrogen agonist activity of the phytoestrogens genistein and daidzein in MCF-7 human breast cancer cells. *J Endocrinol* 197(3): 503-515.
- Radice S, Chiesara E, Frigerio S, Fumagalli R, Parolaro D, Rubino T, et al. 2006. Estrogenic effect of procymidone through activation of MAPK in MCF-7 breast carcinoma cell line. *Life Sci* 78(23): 2716-2723.
- Rey-Roldan EB, Grillo CA, Pietranera L, Libertun C, Nicola AF, Piroli GG. 2008. Levonorgestrel antagonism on estrogen-induced pituitary tumors is mediated by progesterone receptors. *Horm Metab Res* 40(4):245-50.
- Rider CV, Hartig PC, Cardon MC, Wilson VS. 2009a. Comparison of chemical binding to recombinant fathead minnow and human estrogen receptors alpha in whole cell and cell-free binding assays. *Environ Toxicol Chem* 28(10):2175-81.
- Rider CV, Hartig PC, Cardon MC, Wilson VS. 2009b. Development of a competitive binding assay system with recombinant estrogen receptors from multiple species. *Toxicology Letters* 184(2): 85-89.
- Schreihofer DA. 2005. Transcriptional regulation by phytoestrogens in neuronal cell lines. *Mol Cell Endocrinol* 231(1-2): 13-22.

- Seo HS, DeNardo DG, Jacquot Y, Laios I, Vidal DS, Zambrana CR, et al. 2006. Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. *Breast Cancer Res Treat* 99(2): 121-134.
- Shaw LE, Sadler AJ, Pugazhendhi D, Darbre PD. 2006. Changes in oestrogen receptor-alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells. *J Steroid Biochem Mol Biol* 99(1): 19-32.
- Shen O, Du G, Sun H, Wu W, Jiang Y, Song L, et al. 2009. Comparison of *in vitro* hormone activities of selected phthalates using reporter gene assays. *Toxicol Lett* 191(1):9-14.
- Sonneveld E, Riteco JA, Jansen HJ, Pieterse B, Brouwer A, Schoonen WG, et al. 2006. Comparison of *in vitro* and *in vivo* screening models for androgenic and estrogenic activities. *Toxicol Sci* 89(1):173-87.
- Sotoca AM, Ratman D, van der Saag P, Strom A, Gustafsson JA, Vervoort J, et al. 2008. Phytoestrogen-mediated inhibition of proliferation of the human T47D breast cancer cells depends on the ERalpha/ERbeta ratio. *J Steroid Biochem Mol Biol* 112(4-5): 171-178.
- Sumida K, Ooe N, Saito K, Kaneko H. 2003. Limited species differences in estrogen receptor alpha-mediated reporter gene transactivation by xenoestrogens. *Journal of Steroid Biochemistry and Molecular Biology* 84(1): 33-40.
- Sun H, Xu XL, Qu JH, Hong X, Wang YB, Xu LC, et al. 2008. 4-Alkylphenols and related chemicals show similar effect on the function of human and rat estrogen receptor alpha in reporter gene assay. *Chemosphere* 71(3): 582-588.
- Takayanagi S, Tokunaga T, Liu X, Okada H, Matsushima A, Shimohigashi Y. 2006. Endocrine disruptor bisphenol A strongly binds to human estrogen-related receptor gamma (ERRgamma) with high constitutive activity. *Toxicol Lett* 167(2):95-105.
- Takeuchi S, Iida M, Kobayashi S, Jin K, Matsuda T, Kojima H. 2005. Differential effects of phthalate esters on transcriptional activities via human estrogen receptors alpha and beta, and androgen receptor. *Toxicology* 210(2-3): 223-233.
- Takeuchi S, Takahashi T, Sawada Y, Iida M, Matsuda T, Kojima H. 2009. Comparative study on the nuclear hormone receptor activity of various phytochemicals and their metabolites by reporter gene assays using Chinese hamster ovary cells. *Biol Pharm Bull* 32(2): 195-202.
- Tang X, Zhu X, Liu S, Nicholson RC, Ni X. 2008. Phytoestrogens induce differential estrogen receptor beta-mediated responses in transfected MG-63 cells. *Endocrine* 34(1-3): 29-35.
- ter Veld MG, Schouten B, Louisse J, van Es DS, van der Saag PT, Rietjens IM, et al. 2006. Estrogenic potency of food-packaging-associated plasticizers and antioxidants as detected in ERalpha and ERbeta reporter gene cell lines. *J Agric Food Chem* 54(12): 4407-4416.
- Tezuka Y, Takahashi K, Suzuki T, Kitamura S, Ohta S, Nakamura S, et al. 2007. Novel metabolic pathways of p-n-nonylphenol catalyzed by cytochrome P450 and estrogen receptor binding activity of new metabolites. *Journal of Health Science* 53(5): 552.
- Van den Belt K, Berckmans P, Vangenechten C, Verheyen R, Witters H. 2004. Comparative study on the *in vitro/in vivo* estrogenic potencies of 17[beta]-estradiol, estrone, 17[alpha]-ethynylestradiol and nonylphenol. *Aquatic Toxicology* 66(2): 183-195.
- Vivacqua A, Recchia AG, Fasanella G, Gabriele S, Carpino A, Rago V, et al. 2003. The food contaminants bisphenol A and 4-nonylphenol act as agonists for estrogen receptor alpha in MCF7 breast cancer cells. *Endocrine* 22(3): 275-284.

- Wang J, Fang F, Huang Z, Wang Y, Wong C. 2009a. Kaempferol is an estrogen-related receptor alpha and gamma inverse agonist. *FEBS Lett* 583(4): 643-647.
- Wang P, Wen Y, Han GZ, Sidhu PK, Zhu BT. 2009a. Characterization of the oestrogenic activity of non-aromatic steroids: are there male-specific endogenous oestrogen receptor modulators? *Br J Pharmacol* 158(7): 1796-1807.
- Wijayarathne A, Nagel S, Paiger L, Christensen D, Norris J, Fowlkes D, et al. 1999. Comparative analyses of mechanistic differences among antiestrogens. *Endocrinology* 140: 5828-5840.
- Wilkinson JM, Hayes S, Thompson D, Whitney P, Bi K. 2008. Compound profiling using a panel of steroid hormone receptor cell-based assays. *J Biomol Screen* 13(8): 755-765.
- Willemsen P, Scippo ML, Kausel G, Figueroa J, Maghuin-Rogister G, Martial JA, et al. 2004. Use of reporter cell lines for detection of endocrine-disrupter activity. *Anal Bioanal Chem* 378(3): 655-663.
- Witters H, Freyberger A, Smits K, Vangenechten C, Lofink W, Weimer M, et al. 2010. The assessment of estrogenic or anti-estrogenic activity of chemicals by the human stably transfected estrogen sensitive MELN cell line: results of test performance and transferability. *Reprod Toxicol* 30(1): 60-72.
- Wong SP, Li J, Shen P, Gong Y, Yap SP, Yong EL. 2007. Ultrasensitive cell-based bioassay for the measurement of global estrogenic activity of flavonoid mixtures revealing additive, restrictive, and enhanced actions in binary and higher order combinations. *Assay Drug Dev Technol* 5(3): 355-362.
- Wu F, Safe S. 2007. Differential activation of wild-type estrogen receptor alpha and C-terminal deletion mutants by estrogens, antiestrogens and xenoestrogens in breast cancer cells. *J Steroid Biochem Mol Biol* 103(1):1-9.
- Xu H, Kraus WL, Shuler ML. 2008. Development of a stable dual cell-line GFP expression system to study estrogenic endocrine disruptors. *Biotechnol Bioeng* 101(6):1276-87.
- Yamasaki K, Takeyoshi M, Yakabe Y, Sawaki M, Imatanaka N, Takatsuki M. 2002. Comparison of reporter gene assay and immature rat uterotrophic assay of twenty-three chemicals. *Toxicology* 170(1-2): 21-30.
- Yoon K, Pallaroni L, Stoner M, Gaido K, Safe S. 2001. Differential activation of wild-type and variant forms of estrogen receptor alpha by synthetic and natural estrogenic compounds using a promoter containing three estrogen-responsive elements. *Journal of Steroid Biochemistry and Molecular Biology* 78(1): 25-32.
- Yoon K, Pellaroni L, Ramamoorthy K, Gaido K, Safe S. 2000. Ligand structure-dependent differences in activation of estrogen receptor alpha in human HepG2 liver and U2 osteogenic cancer cell lines. *Molecular and Cellular Endocrinology* 162(1-2): 211-220.
- Yu Y, Zhou Q, Hang Y, Bu X, Jia W. 2007. Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells. *Cancer* 109(11): 2374-2382.
- Zhao L, Mao Z, Brinton RD. 2009. A select combination of clinically relevant phytoestrogens enhances estrogen receptor beta-binding selectivity and neuroprotective activities *in vitro and in vivo*. *Endocrinology* 150(2): 770-783.
- Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR. 2006. Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding. *Endocrinology* 147(9): 4132-4150.

Zierau O, Kolba S, Olf S, Vollmer G, Diel P. 2006. Analysis of the promoter-specific estrogenic potency of the phytoestrogens genistein, daidzein and coumestrol. *Planta Medica* 72(2): 184-186.